共 4 条
[1]
Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients[J] Cancer Immunology; Immunotherapy 2007,
[2]
Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide[J] Yasuhide Motoyoshi;Kazuhisa Kaminoda;Ohki Saitoh;Keisuke Hamasaki;Kazuhiko Nakao;Nobuko Ishii;Yuji Nagayama;Katsumi Eguchi Oncology Reports 2006,
[3]
Increased interleukin-10 serum levels in patients with solid tumours[J] Claudio Fortis;Marco Foppoli;Luca Gianotti;Laura Galli;Giovanni Citterio;Giuseppe Consogno;Oreste Gentilini;Marco Braga Cancer Letters 1996,
[4]
Type 1 T helper and type 2 T helper cells: Functions; regulation and role in protection and disease[J] S. Romagnani International Journal of Clinical & Laboratory Research 1992,

